StressMarq biosciences - alpha synuclein oligomer antibody validation

这个项目将允许专门制造抗体的公司StressMarq和克里斯蒂博士在维多利亚大学的实验室研究一种新的α突触核蛋白聚集体。这种聚集了类似于hasprion的特性，并且在活性时能够催化宿主环境中发现的内源性α -突触核蛋白单体在体内形成路易体。路易体是路易体痴呆的标志，通常被描述为帕金森病的一个亚群（大约25%的帕金森患者有这种病理）。该项目将包括利用免疫组织化学在大鼠或小鼠大脑切片上“绘制”抗体的病理表达和活性，这些切片来自不同控制神经背景的动物，这是克里斯蒂实验室的常规工作。与细胞培养一起工作的能力将显示抗体在这些细胞中诱导时是否可以中和路易体病理，如果成功，同样可以在大鼠中进行。

This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'slaboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasprion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromendogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of LewyBody dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'spatients have this pathology). The project will involve "mapping" the expression of the pathology and activityof the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingcontrolled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workwith cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesecells, and if successful, the same could be carried out in rats.